GSPT1 and hemophilia: Antisense oligonucleotides (ASOs) targeting eRF3a promoted modest PTC readthrough in hFIX-R338X hemophilia mice [140], suggesting the potential of targeting eRF3a for the treatment of genetic diseases caused by a nonsense mutation.